values. In an off-target screening 25CN-NBOH (10 µM) displayed either substantially weaker activity or inactivity at a plethora of other receptors, transporters and kinases. In a toxicological screening, 25CN-NBOH (100 µM) displayed a benign acute cellular toxicological profile. 25CN-NBOH displayed high in vitro permeability (P app = 29 x 10 -6 cm/s) and low P-glycoproteinmediated efflux in a conventional model of cellular transport barrier. In vivo, administration of 25CN-NBOH (3 mg/kg, s.c.) in C57 mice produced plasma and brain concentrations of the free (unbound) compound of ∼200 nM within 15 min, further supporting that 25CN-NBOH rapidly penetrates the blood-brain barrier and is not subjected to significant efflux. In conclusion, 25CN-NBOH appears to be a superior selective and brain-penetrant 5-HT 2A receptor agonist compared to DOI, and thus we propose that the compound could be a valuable tool for future investigations of physiological functions mediated by this receptor.
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INTRODUCTION
The neurotransmitter serotonin (5-hydroxytryptamine, 5-HT) is widely distributed in tissue and regulates a broad spectrum of functions throughout the central nervous system (CNS) and in the periphery (Berger et al., 2009) . 5-HT mediates these effects through six classes of G proteincoupled receptors (GPCRs; 5-HT 1 , 5-HT 2 , 5-HT 4 , 5-HT 5 , 5-HT 6 and 5-HT 7 ) comprising a total of 13 receptor subtypes and a class of ligand-gated cation channels (5-HT 3 ) (Hannon and Hoyer, 2008; Millan et al., 2008; McCorvy and Roth, 2015) . The 5-HT 2A , 5-HT 2B and 5-HT 2C receptors (5-HT 2A Rs, 5-HT 2B Rs and 5-HT 2C Rs, respectively) are Gα q -coupled receptors linked to activation of phospholipase C, increased formation of the second messengers inositol triphosphate (IP 3 ) and diacylglycerol, and mobilization of Ca 2+ from intracellular stores, albeit the receptors also signal through other signaling cascades (Roth, 2011; Halberstadt, 2015; McCorvy and Roth, 2015; Maroteaux et al., 2017) .
The 5-HT 2A R is the major postsynaptic 5-HT receptor in the CNS, where it is involved in processes of key importance for memory and cognitive functions, mood, circadian rhythm and appetite (Berger et al., 2009; Zhang and Stackman, 2015) . The receptor constitutes a major drug target in cognitive and psychiatric disorders (Celada et al., 2004; Gonzalez-Maeso and Sealfon, 2009; Meltzer, 2012; Maroteaux et al., 2017) , and it is the main mediator of the psychotropic and psychotomimetic effects of natural hallucinogens such as lysergic acid diethylamide (LSD), psilocybin and mescaline as well as several synthetic drugs (Gonzalez-Maeso and Sealfon, 2009; Halberstadt, 2015; Nichols, 2016; Nichols et al., 2017) . For decades, the hallucinogenic properties possessed by these drugs has hampered the exploration of the therapeutic potential in augmentation of 5-HT 2A R signaling for treatment of CNS disorders. In recent years, however, the remarkable effects mediated by lysergic acid diethylamide (LSD) and psilocybin in rodent models of cognitive and psychiatric disorders and in human treatment trials of depression, post-traumatic stress, obsessive-compulsive disorder, autism and various forms of addiction have substantiated this
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6 twitches in mice (Fantegrossi et al., 2015; Halberstadt et al., 2016) and to elucidate the involvement of the receptor in mitochondrial biogenesis (Harmon et al., 2016) .
In the present study, we have characterized the in vitro pharmacological and pharmacokinetic properties of 25CN-NBOH in detail. 25CN-NBOH and three close structurally related analogs [N- have been subjected to elaborate pharmacological characterization and compared to DOI at recombinant 5-HT 2 Rs in binding and functional assays. Moreover, 25CN-NBOH has been screened for off-target activity at other monoamine receptors and several other putative targets. Finally, the pharmacokinetic characteristics of 25CN-NBOH have been investigated, including the brain and plasma exposure of the drug following administration in mice.
INI receptors, and radioligand binding assays were performed as previously described (Cheng et al., 2016) . Briefly, membranes were resuspended in standard binding buffer (50 mM Tris, 10 mM MgCl 2 , 0.1 mM EDTA, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) and added to 96-well polypropylene plates containing test ligands (1 pM to 100 µM, final concentrations). 3 nM, concentration range 2.5-3.3 nM) was used. Reactions were incubated at 37°C for 2 hours in the dark to reach equilibrium and terminated by harvesting onto 0.3% PEI-soaked Filtermax GF/A filters (Wallac). Filters were washed three times with ice-cold harvest buffer (50 mM Tris, pH 7.4), dried, and Melitilex (Perkin Elmer) scintillant was applied.
Filters were counted on a Wallac TriLux microbeta counter (1 min/well). Bound radioligand was plotted as a function of log [ligand] and data were analyzed using a one-site Ki model built into Prism 5.0 (Graphpad software). HT 2C R using [ 3 H]Cimbi-36 as radioligand were determined at membranes from tsA201 cells transiently expressing the two receptors. 36-48 hours after the transfection, the tsA201 cells were harvested and scraped into ice-cold assay buffer (50 mM Tris-HCl, 4 mM CaCl 2 , pH 7.4), homogenized with a Polytron homogenizer for 10 s, and centrifuged for 20 min at 50.000 g at 4 °C.
Cell pellets were re-suspended in fresh assay buffer, homogenized, and centrifuged at 50.000 g for another 20 min, after which the membranes were stored at −80 °C until use. On the day of the assay, the cell membranes were re-suspended in assay buffer and incubated with 
HT 2C R (K D = 1.5 nM), respectively. Non-specific binding was determined using 20 µM mianserin, and the assay volume was 1 ml. The reactions were incubated for 2 h at room temperature while shaking. Whatman GF/C filters were presoaked for 1 h in a 0.2% polyethylenimine solution, and binding was terminated by filtration through the filters using a 48-well Brandel cell harvester and four washes with 4 ml of ice-cold isotonic NaCl solution. After this, the filters were dried, 3 ml of Opti-Fluor (PerkinElmer) was added, and the amount of bound radioactivity was determined in a scintillation counter.
IP-One HTRF assay. The ligands were characterized functionally at the stable 5-HT 2A R-and 5-HT 2C R-HEK293 cell lines in the IP-One HTRF assay (Nørskov-Lauritsen et al., 2014) essentially as previously described (Jensen et al., 2013; Hansen et al., 2015) . On the day of the experiment subconfluent cells were washed one time with Phosphate-Buffered Saline and detached from the cell culture plate using dissociation buffer (Sigma-Aldrich plate reader (Molecular Dynamics), which has been previously described (Cheng et al., 2016) .
Briefly, cells were seeded (10,000 cells per well in 40 µL volume) into poly-L-lysine coated 384-well black plates followed by addition of 2 µg/mL tetracycline to induce receptor expression. On the day of the assay, the medium was decanted and replaced with drug buffer (20 µL/well, 1X
HBSS, 20 mM HEPES, 0.1% BSA, 0.01% ascorbic acid, pH 7.4) containing Fluo-4 Direct Dye (Invitrogen). Plates containing dye were incubated for 1 h at 37°C. Afterwards, cells were challenged with 10 µL/well of drug (concentration range 1 pM to 32 µM) at 3X final concentration diluted in drug buffer. Calcium flux was measured (1 read/s) for 300 s. Fluorescence in each well was normalized to the average of the first 10 reads, and maximum-fold increase was determined.
Fold over baseline was plotted as a function of drug concentration. Data were normalized to %5-HT stimulation and analyzed using log[agonist] vs response in Graphpad Prism 5.0. Ca 2+ Assay II. The test and reference ligands were characterized functionally at the stable 5-HT 2A R-and 5-HT 2C R-HEK293 cell lines in this assay essentially as previously described (Jensen et al., 2013) . Briefly, the cells were split into poly-D-lysine-coated black 96-well plates with clear bottom (6 x 10 4 cells/well). The following day the culture medium was aspirated and the cells were incubated in 50 µl assay buffer [HBSS containing 20 mM HEPES, 1 mM CaCl 2 , 1 mM MgCl 2 and 2.5 mM probenecid, pH 7.4] supplemented with 6 mM Fluo-4/AM at 37 °C for 1 h. Then the buffer was aspirated, the cells were washed once with 100 µl assay buffer, and then 100 µl assay buffer was added to the cells (in the antagonist experiments the antagonist was added at this point (Black and Leff, 1983) can be used to compare the relative potencies of full to partial agonists through the parameter Δlog(τ/K A ), which specifically is the difference in the logarithms of the ratio of the efficacy (τ) and the equilibrium-dissociation constant (K A ) of the two relevant agonists. A further simplification of this parameter can be made if the slopes of the agonist concentrationresponse curves are not significantly different from unity. As shown by Black et al. (1985) , the maximal response to an agonist is given by: (Black et al., 1985) …
Similarly, the EC 50 for an agonist is given by:
It can be seen that for n = 1, equations 1 and 2 yield a ratio R max /EC 50 = τ/K A . Therefore, Δlog(R max /EC 50 ) values furnish system independent values to compare the relative activity of agonists (Kenakin, 2017) .
In vitro screening of 25CN-NBOH at various targets. The selectivity profile of 25CN-NBOH
(1) was investigated in radioligand binding assays at numerous targets performed by the National Toxicology screening. The cellular toxicity was investigated in a high content screening assay where the effects of 25CN-NBOH at concentrations up to 100 µM at six parameters (nuclei counts, nuclear area, plasma membrane integrity, lysosomal activity, mitochondrial membrane potential and mitochondrial area) was determined (Persson et al., 2013) .
Solubility. The solubility and stability of 25CN-NBOH at pH 7.4 was determined.
Membrane permeability, intrinsic clearance, and plasma protein and brain tissue binding. The bidirectional permeability of 25CN-NBOH was measured in the Madin-Darby canine kidney (MDCK) cell line expressing human multidrug resistance protein (MDR1; P-glycoprotein) in triplicate as described previously (Risgaard et al., 2013) . The permeability assessment was performed at 37 °C over a 60-min period at a concentration of 0.5 µM applied to the apical or basolateral side of the cell monolayer. The efflux ratio was calculated as the ratio between the permeability in the basal-to-apical direction divided by the permeability in the apical-to-basal direction. The murine intrinsic clearance (MCL int ) of 25CN-NBOH, in L/kg/h, was calculated from its half-life in the presence of murine microsomes, as previously described (Leth-Petersen et al., 2014) . The free fraction of 25CN-NBOH in mouse plasma and brain tissue was determined in vitro at 37°C in triplicate using equilibrium dialysis as described previously (Redrobe et al., 2014) . The assay was performed using a test compound concentration of 1 µM incubated for 5 h.
Plasma and brain exposure analysis. Three groups of male C57BL/6 mice (20-25 g, obtained from Charles River, Germany) were dosed subcutaneously with 3 mg/kg of 25CN-NBOH. The compound was dissolved in 20% hydroxypropyl-β-cyclodextrin dosed in a volume of 10 ml/kg.
Plasma and brain samples were taken from each group at 5, 15 or 30 min after drug administration (n=3). Under isoflurane anesthesia, cardiac blood was obtained in EDTA-coated tubes and centrifuged for 10 minutes at 4°C, after which plasma was harvested. After decapitation, the brain
13 was removed and gently rinsed on filter paper and frozen together with plasma specimens at -80°C until analysis. Brain homogenate was prepared by homogenizing the brain with 4 volumes of deionized water using isothermal focused acoustic ultrasonication (Covaris Inc., Woburn, MA).
Quantitative bioanalysis was performed using ultra-performance liquid chromatography (UPLC) (Waters, Milford, MA) coupled to tandem mass spectrometry (Sciex 4000; AB Sciex, Foster City, CA This article has not been copyedited and formatted. The final version may differ from this version. Since previous studies have found binding affinities exhibited by agonists at 5-HT 2A R and other
GPCRs to be highly dependent on the intrinsic activity of the radioligand used (Rosenkilde et al., 1994; Hjorth et al., 1996; Sleight et al., 1996; Sagan et al., 1997; Rosenkilde and Schwartz, 2000) , the binding affinities of the compounds were determined using both antagonist ( (Tables 1 and 2 (Table 3 , Figure 3A ). In fact, even the absolute EC 50 values displayed by the compounds at the receptors were strikingly similar between the two assays (Table 3) .
Analogously to their profiles in the [ 3 H]IP 1-3 assay, 25CN-NBOH (1) and 25CN-NBOMe (2) were only slightly more potent 5-HT 2A R agonists (∼2-fold) than DOI in the IP-One assay, and thus it was primarily the 7.6-and 5-fold higher EC 50 values exhibited by 1 and 2 compared to DOI at 5-HT 2C R that gave rise to their higher 5-HT 2A R/5-HT 2C R selectivity ratios (Table 3 , Figure 3A ). 25CN-NBF and 25CN-NBOMe (2) were full agonists at the 5-HT 2C R, whereas 25CN-NBF (3) and 25CN-NBMD (4) were partial agonists. Thus, the intrinsic activities of the five compounds in the IP-One assay were also in concordance with those determined for the agonists in the IP turnover assay (Table 3) .
Next the functional properties of the four analogs, DOI and a couple of other reference 5-HT 2 R agonists were characterized at human 5-HT 2A , 5-HT 2B and 5-HT 2C receptors in two fluorescencebased Ca 2+ imaging assays (Ca 2+ Assays I and II). Analogously to the IP assays, the functional readout in these assays is a reflection of Gα q -mediated receptor signaling (measured further downstream in the signaling cascade). However, in contrast to the IP assays functional responses in the Ca 2+ assay are recorded in real-time and not as end-point measurements. Moreover, although the two Ca 2+ assay protocols used in this study were essentially identical, the assays were performed using different 5-HT 2A R-, 5-HT 2B R-and 5-HT 2C R-expressing cell lines and in different labs, and thus the two data sets for the compounds from these assays serve to probe the importance of these differences for the functional properties displayed the agonists. In previous studies we have found the functional properties exhibited by the three 5-HT 2 Rs in both combinations of cell lines and assays to be in good agreement with literature data for the receptors (Jensen et al., 2013; Cheng et al., 2016) .
The rank orders of agonist potencies displayed by DOI and the four analogs at 5-HT 2A R and 5-HT 2C R were the same in the two Ca 2+ assays, and these were also the same as in the two IP assays: Figure 3B ).
This article has not been copyedited and formatted. The final version may differ from this version. (Table 4) . and DOI in the Ca 2+ assay I were also examined using Δlog(R max /EC 50 ) values ( Figure 4D ). All four analogs displayed considerably higher 5-HT 2A R selectivities than DOI, the rank order being 25CN-NBF > 25CN-NBMD > 25CN-NBOH > 25CN-NBOMe ( Figure 4D ).
5-HT
Screening of 25CN-NBOH at other putative molecular targets.
The possible existence of other targets for 25CN-NBOH than the 5-HT 2 Rs was investigated in a comprehensive screens of the compound (at an assay concentration of 10 µM) at a plethora of neurotransmitter receptors and transporters, ion channels and enzymes in radioligand binding assays and at a broad spectrum of kinases and other enzymes in enzyme assays. The complete data sets from these screens are given in Supporting Information (SI) Table 1 , and the targets where 25CN-NBOH (10 µM) displayed significant activity are summarized in Table 5 . In addition to its nanomolar binding affinities to the receptors. 25CN-NBOH (10 µM) also inhibited radioligand binding to other targets to approximately 50%, thus displaying estimated IC 50 values of 10 µM at these targets (SI Table 1 ).
However, the compound was inactive at the majority of targets included in the radioligand binding screening. Finally, 25CN-NBOH was also tested at a wide range of kinases and other enzymes in enzymatic assays, displaying no significant activity at any of these at an assay concentration of 10 µM (SI Table 1 ). In addition, we found that 25CN-NBOH inhibited hERG with an IC 50 value of 2.7 µM.
It is important to stress that lack of inhibition of radioligand binding to a specific target in these assays not necessarily reflects inactivity of the test compound at the target, since the compound potentially could bind to a site distinct from the site targeted by the radioligand without affecting its binding. However, the majority of targets assayed by radioligand binding in the screening were class A GPCRs, and considering that few allosteric ligands of these receptors have been reported not to affect orthosteric radioligand binding (Keov et al., 2011) , we propose that these receptor binding data are likely to be highly predictive of the functional activity of 25CN-NBOH at these targets. Moreover, 25CN-NBOH would be expected to be most likely to act through the orthosteric sites of the monoaminergic and muscarinic acetylcholine receptors included in this screening, and thus its ability to compete with orthosteric radioligands for binding is a direct measurement of its activity at these receptors.
Solubility. The solubility of 25CN-NBOH at pH 7.4 was determined to be 405 µg/mL. However, we have been able to make stock solution for in vivo investigation with concentrations up to 3 mg/mL in physiological saline (0.9% NaCl) by sonication and up to 5 mg/mL if 5% DMSO was added. Upon storage at 5°C some precipitation was seen but sonication caused the compound to redissolve. 25CN-NBOH is stable for at least several weeks when stored and handled in this way as judged by LC-MS analysis at various time points.
Toxicology screening. In the high content screening of 25CN-NBOH for acute cellular toxicity, no effects were seen for 25CN-NBOH at any of the six parameters tested (nuclei counts, nuclear area, plasma membrane integrity, lysosomal activity, mitochondrial membrane potential and To assess the global selectivity profile of 25CN-NBOH, the compound (10 µM) was subjected to an elaborate screening at a plethora of other putative targets in radioligand binding and enzyme assays (Table 5 and SI Table 1 ). There was a considerable overlap between targets assayed in the Eurofins and PDSP screenings, and for these targets only a few insignificant differences are observed between the two data sets. The screening results are also in good agreement with data reported for the compound (screened at a concentration of 1 µM by PDSP) in a recent study, the only substantial differences between the two data sets being the observed activity of 25CN-NBOH at H 2 histamine (K i 674 nM) and β 2 adrenergic (K i 720 nM) receptors reported by Halberstadt et al. (2016) which contrast the inactivity of the compound at these receptors in this study (IC 50 >10 µM).
This article has not been copyedited and formatted. The final version may differ from this version. Regardless of which of these values are correct, 25CN-NBOH displayed ≥100-fold higher binding affinities to 5-HT 2A R than to all "non-5-HT 2 R" targets in the screening, and thus the compound seems to be highly selective for 5-HT 2 Rs, and in particular for 5-HT 2A R.
The pharmacokinetic characteristics displayed by 25CN-NBOH combined with the levels of brain exposure of the drug following systemic administration in mice suggest that the compound is well suited as a pharmacological tool in in vivo studies of 5-HT 2A Rs. 25CN-NBOH was found to rapidly cross the cellular barrier and not to be a substrate for P-glycoprotein-mediated efflux in MDCK-MDR1 monolayers, a well-established in vitro model of the blood-brain barrier (Feng et al., 2008) . Based on its high MCL int we expected 25CN-NBOH to be cleared extremely fast in vivo, even with s.c. dosing, but our in vivo exposure study showed that 25CN-NBOH (3 mg/kg, s.c.)
rapidly reached the CNS yielding a high-nanomolar concentration of the unbound drug that was fairly stable over time, at least until 30 min after administration ( Figure 5B ).
While the rapid exposure of the high levels of free 25CN-NBOH in the brain following systemic administration demonstrates the feasibility of using the agonist for in vivo studies, it also raises the question what the optimal dose range for 25CN-NBOH in such studies would be. 25CN-NBOH has been applied in two recent in vivo studies, where Halberstadt et al. (2016) used doses ranging from 0.3 to 6 mg/kg s.c. in C57BL/6J mice and Fantegrossi et al. (2015) used doses ranging from 0.1 to 30 mg/kg i.p. in NIH Swiss mice. However, since neither of the two studies determined the brain exposure levels of the drug arising from these doses, the levels of 5-HT 2A R activation underlying its behavioral effects were not addressed (Fantegrossi et al., 2015; Halberstadt et al., 2016) . Our exposure study was partly designed to approximate the experimental conditions used by Halberstadt et al. (2016) but more importantly we wanted an overall insight into the correlation between 25CN-NBOH dosing and the resulting brain exposure of the free drug. 25CN-NBOH (3 mg/kg, s.c.)
produced rapidly increasing concentrations of free drug in mice brains, peaking at ~200 nM after 15 min and remaining at this level for some time ( Figure 5B ). It should be noted that the determined As mentioned in the Introduction, there is an increasing interest in psychedelics and 5-HT 2A R agonists as putative therapeutics, not only when it comes to numerous psychiatric disorders but also for the treatment of addiction and alcoholism, cluster head aches and various inflammatory disorders (Sewell et al., 2006; Yu et al., 2008; Nau et al., 2013; Hendricks et al., 2014; Bogenschutz et al., 2015; Nau et al., 2015; Nichols, 2016) . Although there is little doubt that the 5-HT 2A R is the main mediator of these in vivo effects, the agonist properties exhibited by these drugs at 5-HT 2B , 5-HT 2C and other 5-HT receptors on the other hand suggest that additional receptors could be activated to some degree within the 5-HT 2A R-effective concentration range and thus potentially contribute to the observed effects. While these putative contributions in previous This article has not been copyedited and formatted. The final version may differ from this version. - 
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The binding assays were performed as described in Materials and Methods. K i values are given in nM with pK i ± S.E.M. values in brackets with the number of experiments (n) for each binding affinity given in superscript.
This article has not been copyedited and formatted. The final version may differ from this version. - - 
The functional assays were performed as described in Materials and Methods. - Table 5 . Pharmacological properties displayed by 25CN-NBOH (1) at selected receptor targets in radioligand binding assays in broad profiling screens at Eurofins and PDSP (data indicated by "E"
and "P", respectively). The data included in this various targets in radioligand binding and enzymatic assays in broad profiling screens at Eurofins and PDSP (data indicated by "E" and "P", respectively). The inhibition mediated by 25CN-NBOH (10 µM) in competition binding assays to various receptors, transporters, ion channels and enzymes are given in % (positive and negative values representing % inhibition and % potentiation relative to control, respectively) with the estimated K i or IC 50 values at the various targets. In the binding assays radioligand concentrations near or at the K D value for the radioligand at the specific target were used. The inhibition mediated by 25CN-NBOH (10 µM) in enzymatic assays to various recombinant kinases and other enzymes are also given. An inhibition of >50% is considered significant by Eurofins. The data are given as the mean values based on 2 independent determinations. h, human; r, rat; gp, guinea pig.
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Enzyme assays
25CN-NBOH (10 µM) was inactive [inhibition ranging between -23% and 16 %] at a broad selection of human recombinant kinases in enzymatic assays: Abl, ALK, AMPKα, ASK1, CamK, CDK1/cyclinB, CDK6/cyclinD3, CDK7/cyclinH/MAT1, CDK9/cyclin T1, CHK1, CK1γ1, CK2α2, DRAK, EGFR, EphA5, EphB4, Fyn, GSK3β, HER2/ErbB2, IKKα, InsR, IRAK4, JAK2, KDR, LOK, Lyn, MEK1, MKK7β, MLK1, Mnk2, MSK2, MST1, mTOR, NEK2, p38α, p70S6K, PAK2, PDGFRβ, PKA, PKBβ, PKCα, PKCθ, PKG1α, Plk3, PRAK, Rse, Rsk1, SAPK2a, SRPK1, TAK1 and PI3 kinases p110β/p85α, p120γ, p110δ/p85α and p110α/p85α (all [-7] and acetylcholinesterase [43%] (all tested by Eurofins).
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